• 1
    Douglass EC, Reynolds M, Finegold M, et al Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993; 11: 96-99.
  • 2
    Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group. J Clin Oncol. 1991; 9: 2167-2176.
  • 3
    Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991; 9: 1050-1058.
  • 4
    Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a Pediatric Oncology Group phase II study. J Clin Oncol. 2002; 20: 3438-3444.
  • 5
    Dall'Igna P, Cecchetto G, Dominici C, et al. Carboplatin and doxorubicin (CARDOX) for nonmetastatic hepatoblastoma: a discouraging pilot study. Med Pediatr Oncol. 2001; 36: 332-334.
  • 6
    Mollman JE, Glover DJ, Hogan WM, et al. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer. 1988; 61: 2192-2195.
  • 7
    Wadler S, Beitler JJ, Rubin JS, et al. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study. J Clin Oncol. 1993; 11: 1511-1516.
  • 8
    Malogolowkin M, Katzenstein HM, Krailo M, et al. Intensive versus standard platinum therapy for the treatment of children with hepatoblastoma (HB): a report of the Intergroup Hepatoblastoma Study P9645 [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 799. Abstract 8516.
  • 9
    Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005; 104: 841-847.
  • 10
    Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004; 40: 2445-2451.
  • 11
    Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991; 19: 295-300.
  • 12
    Bishop YMM, Feinberg SE, Holland PMW. Discrete Multivariate Analysis. Cambridge, Mass: MIT Press; 1975.
  • 13
    Armitage P, Berry G. Statistical Methods in Medical Research. Palo Alto, Calif: Blackwell Scientific; 1998.
  • 14
    Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons, Inc; 1980.
  • 15
    Malogolowkin MH, Katzenstein H, Krailo MD, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol. 2006; 24: 2879-2884.
  • 16
    Koukourakis MI. Amifostine: is there evidence of tumor protection? Semin Oncol. 2003; 30: 18-30.
  • 17
    Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996; 14: 2101-2112.
  • 18
    Fisher MJ, Lange BJ, Needle MN, et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer. 2004; 43: 780-784.
  • 19
    Petrilli AS, Oliveira DT, Ginani VC, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol. 2002; 24: 188-191.
  • 20
    Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008; 26: 3749-3755.